Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0003864 (arthritis)
 69,039 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Benoxaprofen is a potent and long-acting anti-inflammatory and antipyretic compound. Its anti-inflammatory activity has been demonstrated in carrageenan-induced oedema, in cellulose pellet granuloma and in both developing and established adjuvant arthritis tests in rats. Its antipyretic activity is greater than either aspirin or paracetamol in tests inducing pyrexia with yeast of 'E' pyrogen in rats and rabbits. Benoxaprofen has analgesic activity in tests where pain is accompanied by inflammation but not in other experimental models of pain. The weak prostaglandin synthetase inhibiting properties of this compound differentiate it from other acid anti-inflammatory compounds. The low ulcerogenic potential of benoxaprofen seen in animal models may be related to its relative inability to inhibit PG synthetase.
 ...
PMID:The pharmacology of benoxaprofen (2-[4-chlorophenyl]-alpha-methyl-5-benzoxazole acetic acid), LRCL 3794, a new compound with antiinflammatory activity apparently unrelated to inhibition of prostaglandin synthesis. 1 68

A consistent and reproducible polyarthritis was induced in mice by immunizing them with type II collagen in Complete Freunds adjuvant (CFA) and Bacillus Calmette-Guerin (BCG) vaccine. Several inbred strains of mice were investigated for the ability to develop collagen induced arthritis (CIA). DBA/1 mice (H-2q) produced the highest incidence and the most severe arthritis of all the strains examined. Viable BCG vaccine was essential for the induction of a reproducible disease in this strain. The effects of some anti-inflammatory and anti-rheumatic compounds were examined on the developing and established lesions of CIA. These effects were determined by assessing the paw inflammation using a subjective scoring system and measuring foot weight. Furthermore, levels of serum amyloid P component (SAP) were also determined. Benoxaprofen, cyclophosphamide, indomethacin and prednisolone inhibited the paw inflammation in the developing disease whilst the anti-rheumatic compounds auranofin and D-penicillamine exacerbate the paw inflammation. Cyclophosphamide and prednisolone inhibited the established lesions but only prednisolone prevented the development of further lesions in the established disease. The SAP levels in the prednisolone treated group were also reduced. Auranofin treatment exacerbated the inflammation of both the established and the developing lesions in the same animal. D-penicillamine was inactive in the established disease.
 ...
PMID:Studies on type II collagen induced arthritis in mice. 309 98

We investigated the therapeutic effect of two gold salts, gold sodium thiomalate (GST, i.m.) and auranofin (p.o.), D-penicillamine (p.o.) and benoxaprofen (p.o.) in rat collagen-induced arthritis using type II collagen from fetal bovine articular cartilage. GST, but not auranofin, reduced hind paw edema and bone pathology. However, auranofin reduced serum copper and zymosan-induced prostaglandin production from peritoneal macrophages. In contrast, GST increased both serum copper and macrophage prostaglandin production by zymosan. Benoxaprofen reduced both hind paw edema and pathology, whereas D-penicillamine was without effect. None of these treatments influenced the circulating level of antibody to type II collagen.
 ...
PMID:Effect of gold salts, D-penicillamine and benoxaprofen on type II collagen-induced arthritis in rats. 643 77

Comparative studies with nonsteroidal antiinflammatory drugs (NSAIDs) have shown benoxaprofen to be moderately active in inhibiting carrageenin-induced pleurisy in rats and cellular migration in vitro. Benoxaprofen was also moderately active in inhibiting developing adjuvant-induced arthritis; however, it exhibited a potent response in established adjuvant arthritis, and it was the only compound tested which showed marked inhibition of the directional movement of mononuclear cells. Unlike other NSAIDs, it was a weak inhibitor of prostaglandin synthetase. The data suggested that there may be mechanisms of antiinflammatory activity which do not relate to inhibition of prostaglandin synthetase.
 ...
PMID:The comparative pharmacology of benoxaprofen. 677 99

The effects of some commonly used anti-inflammatory and anti-arthritic drugs on the inflammatory and immunological manifestations of type II collagen-induced arthritis in rats were studied. Among the anti-inflammatory drugs tested at a given dosage (mg/kg/day), benoxaprofen (10), aspirin (25) and indomethacin (3) inhibited the hind paw swelling and anti-type II collagen antibody formation in type II collagen-treated rats. Benoxaprofen also inhibited the delayed type hypersensitivity (DTH) response to type II collagen. Phenylbutazone (30) and fenoprofen (40) partially suppressed the paw swelling, but had no significant effect on humoral and cellular responses. Among the other anti-arthritic drugs, levamisol (25), chloroquine (25) and D-penicillamine significantly suppressed the paw swelling, anti-type II collagen antibody titres and DTH response. Gold chlorophosphene (10) and colchicine (3) had no effect on any of these three parameters. Paramethasone (0.1), cyclophosphamide (1) and azathioprine (10) were very effective when dosed daily, or once (at a different dose) 72 hr prior to immunization with type II collagen.
 ...
PMID:Effects of various anti-inflammatory drugs on type II collagen-induced arthritis in rats. 697 43

The effects of benoxaprofen and some other anti-inflammatory drugs on the inflammatory, cellular, and humoral components of type II collagen-induced arthritis in rats were studied. At the given dosage (mg/kg/day), benoxaprofen (10), aspirin (25), and indomethacin (3) inhibited the hindpaw swelling and development of anti-type II collagen antibodies in collagen-treated rats. Benoxaprofen also inhibited the delayed-type hypersensitivity response to collagen. Phenylbutazone (30) failed to show significant effect on these parameters. The treatment of rats with benoxaprofen throughout the test period or during days 14 to 28 was more effective than the treatment in the initial phases only.
 ...
PMID:Effects of benoxaprofen on the inflammatory, humoral and cellular components of type II collagen-induced arthritis in rats. 697 80

The effects of single or multiple oral administration of benoxaprofen on the gastric mucosa of stressed and unstressed rats and pigs were compared with other nonsteroidal anti-inflammatory drugs. The results showed that benoxaprofen had low ulcerogenic activity when compared with other drugs of low (e.g. azapropazone, fenclofenac) or high (e.g. aspirin, diclofenac, indomethacin) ulcerogenicity. The low ulcerogenicity of benoxaprofen observed in rats also was confirmed in ten-day studies in pigs. Benoxaprofen showed relatively little interaction with physical stress (in rats exposed to cold). Likewise, no enhancement in ulcerogenicity was observed in experimentally induced disease stress states (i.e. in adjuvant arthritis rats), or following acute or chronic oral administration of alcohol, given concurrently with the drug. Little gastric mucosal damage was observed following acute or chronic parenteral (subcutaneous or intraperitoneal) administration of the sodium salt of benoxaprofen to stressed (cold, 4 degrees C) or unstressed rats. This observation combined with evidence of good absorption of the drug suggests that the relatively low ulcerogenicity of benoxaprofen may be due to its intrinsic biochemical properties. The low activity of benoxaprofen as an inhibitor of prostaglandin synthesis may be one factor contributing to this low ulcerogenic activity.
 ...
PMID:A profile of the gastric ulcerogenic activity of benoxaprofen compared with other nonsteroidal anti-inflammatory drugs in rats, stressed or given alcohol, and in pigs. 708 78

The ability of benoxaprofen to suppress bone damage associated with adjuvant-induced arthritis in rats was studied radiographically over a 49-day period. Benoxaprofen was administered orally at a daily dose of 30 mg/kg. Treated and control groups of rats were examined at seven-day intervals from 14 through 49 days. Benoxaprofen showed significant suppression of bone damage at all time intervals. Benoxaprofen was compared in a radiographic bone study with other nonsteroidal anti-inflammatory agents. Benoxaprofen at doses of 10-40 mg/kg/day orally, administered from days 15 to 39 of the disease, was more effective in suppressing bone damage exhibiting toxic effects than other agents. This modification of the experimental disease process by benoxaprofen may be due in part to its reported ability to suppress monocyte migration into inflammatory sites.
 ...
PMID:Radiographic studies of the effect of benoxaprofen on bone damage in the adjuvant arthritic rat. 708 79

Benoxaprofen, a new nonsteroidal anti-inflammatory agent recently marketed as an an antirheumatic drug, has been reported to suppress leucocyte migration into inflammatory sites, possibly by its reported inhibition of leukotriene synthesis. Benoxaprofen is also a weak to moderate inhibitor of prostaglandin synthesis. The effect of benoxaprofen was examined on adjuvant-induced arthritis in rats by radiographic assessment of bone damage. The effect of benoxaprofen was compared to other nonsteroidal anti-inflammatory agents, considered to act primarily by the inhibition of synthesis and/or release of prostaglandins. Drugs were administered from the 15th to the 30th day after induction of the adjuvant disease ('established adjuvant'). Radiographs of adjuvant rats showed extensive bone damage that was markedly suppressed by 30-40 mg/kg of benoxaprofen. Benoxaprofen exerted a dose-related inhibition of bone damage. There was less suppression of bone damage by comparable doses of phenylbutazone, oxyphenbutazone, ibuprofen, fenbufen, naproxen, tolectin and sulindac. Indomethacin, piroxicam and flurbiprofen were nearly as effective but only in doses that produced adverse effects or death in rats. Benoxaprofen may modify the progression of the experimental arthritic disease through a suppression of leucocyte migration.
 ...
PMID:Comparative effects of benoxaprofen and other anti-inflammatory drugs on bone damage in the adjuvant arthritic rat. 713 58

Benoxaprofen (Opren) is a nonsteroidal anti-inflammatory agent used in the treatment of arthritis. Photosensitivity, including onycholysis, has been reported in the rheumatologic literature. This drug has recently been approved for use in the United States under the name of Oraflex. In order to alert the dermatology community, we report a case of photo-onycholysis which developed in a patient being treated with benoxaprofen and review the data on this drug and its side effects.
 ...
PMID:Benoxaprofen-induced photo-onycholysis. 714 76


1